34 unknown, 24 recruiting, 6 completed, 5 active not recruiting. 59 Phase 2, 17 Phase 1, 9 Phase 3, 1 Not applicable, 1 Phase 4.
Follow JS001: new trials by email Literature Review of JS001 trials Research Report on JS001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 1 | Recruiting | Metaclipse Therapeutics Corporation | 30 | 2026-10-01 | 2026-10-27 |
| Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status Toripalimab, Paclitaxel - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 2 | Not yet recruiting | Barbara Ann Karmanos Cancer Institute | 22 | 2026-09-30 | 2026-08-31 |
| AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer Toripalimab, Paclitaxel, Cisplatin - Esophageal Cancer | Not yet recruiting | Henan Cancer Hospital | 400 | 2026-07-30 | 2026-08-11 | |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer Propranolol Hydrochloride, Toripalimab, Chemotherapy - Resectable Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 9 | 2026-06-01 | 2026-10-21 |
| A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma JS212, JS001, 5-FU - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 280 | 2026-04-13 | 2026-04-22 |
| Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC Probiotic, Disitamab Vedotin, Toripalimab - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | chenxu | 146 | 2026-03-26 | 2026-03-17 |
| PDT For Induction Therapy For Head And Neck Cancer Toripalimab-tpzi, Cisplatin, Docetaxel - Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 26 | 2026-03-09 | 2026-10-19 |
| FMD and Neoadjuvant Chemo-immunotherapy in TNBC Fasting-mimicking diet, Chemotherapy, Toripalimab - Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 80 | 2026-03-05 | 2026-04-21 |
| Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC toripalimab, capecitabine - Esophageal Cancer, Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 242 | 2025-09-10 | 2026-04-21 |
| Toripalimab With Chemotherapy for Sinus Cancer Toripalimab, Carboplatin, Docetaxel - Sinonasal Cancer, Paranasal Sinus Neoplasms | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 20 | 2025-06-17 | 2026-08-31 |
| Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer Disitamab Vedotin, RC148, Albumin-bound Paclitaxone - Breast Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 40 | 2025-02-10 | 2025-02-17 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma 9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 60 | 2025-01-17 | 2025-03-21 |
| Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer Disitamab Vedotin, Toripalimab - Breast Neoplasms | Phase 2 | Withdrawn | RemeGen Co., Ltd. | 2024-12-20 | 2024-08-23 | |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer Toripalimab, Cisplatin, Gemcitabine - Nasopharyngeal Cancer Recurrent | Phase 4 | Recruiting | Coherus Oncology, Inc. | 100 | 2024-11-01 | 2026-07-30 |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment JS001, JS004, JS007 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Fudan University | 117 | 2024-04-30 | 2024-04-17 |
| To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer Disitamab Vedotin for Injection, Toripalimab, Epirubicin - Breast Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 79 | 2024-04-29 | 2024-05-23 |
| Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Toripalimab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor | Phase 2 | Active not recruiting | Sun Yat-sen University | 64 | 2023-12-01 | 2026-11-12 |
| DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer Disitamab Vedotin Injection, Pertuzumab Injection, Toripalimab - Breast Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 40 | 2023-11-28 | 2025-10-01 |
Showing 20 of 79. Sign in to see all of them.
Nasopharyngeal Carcinoma (8) · Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (7) · Head and Neck Neoplasms (6) · Stomach Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Transitional Cell (4) · Esophageal Neoplasms (4) · Nasopharyngeal Neoplasms (4) · Colorectal Neoplasms (3) · Melanoma (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Squamous Cell (2) · Esophageal Squamous Cell Carcinoma (2) · Hypopharyngeal Neoplasms (2)
Sun Yat-sen University (11) · RemeGen Co., Ltd. (10) · Fudan University (8) · Shanghai Junshi Bioscience Co., Ltd. (4) · Peking University (3) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Taizhou Hospital (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Ascentage Pharma Group Inc. (1) · BGI, China (1) · Barbara Ann Karmanos Cancer Institute (1) · Cancer Hospital of Guangxi Medical University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Coherus Oncology, Inc. (1)
China (66) · United States (7) · Canada (1)
Jianmin Fang, Ph.D (3) · Lin Shen (2) · Na Su, PhD (2) · Rui-hua Xu, PhD (2) · Sheng Yao, PhD (2) · Ammar Sukari, M.D. (1) · Changling Li (1) · Chao-su Hu, M.D. (1) · Chaosu Hu, M.D. (1) · Chong Zhao (1) · Chong Zhao, M.D (1) · Chong Zhao, MD PhD (1) · Christopher Pack, PhD (1) · Dingwei Ye, Doctor (1) · Dong Wang, PH.D (1)
PMID 19171491, PMID 23510863, PMID 25213161, PMID 25981818, PMID 26755520, PMID 30522017, PMID 30642373, PMID 32086343, PMID 32224416, PMID 34051177, PMID 34782428, PMID 36990609, PMID 37596191, PMID 38167937, PMID 38237373, PMID 38265030, PMID 38710003, PMID 38713205, PMID 38740030, PMID 38969879, PMID 39972105, PMID 41124210
P30CA014089 (1)